[1] |
XIE Rui, GENG Zihan, BAO Lei, ZHAO Ronghua, LI Shuran, SUN Qiyue, WANG Xinwei, ZHANG Jingsheng, CUI Xiaolan, GUO Shanshan, SUN Jing.
Research Progress in Pharmacological Actions, Mechanisms, Structural Modifications and Targeted Formulations of Ribavirin
[J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 950-955.
|
[2] |
CHEN Yaozhe, ZHAN Yunli, SONG Xingdong, ZHU Manyu, OU Xuemei, LI Chuyun.
48 Cases of Hematological Adverse Reactions Associated with Piperacillin Sodium and Tazobactam Sodium
[J]. Chinese Journal of Pharmacovigilance, 2025, 22(7): 794-798.
|
[3] |
LIU Ming, ZHENG Li, ZHANG Weina, SUN Xuelin, TIAN Jinhui, ZHAO Yan.
Research Progress in Biological Activity and Mechanisms of Pachymic Acid
[J]. Chinese Journal of Pharmacovigilance, 2025, 22(7): 826-830.
|
[4] |
ZHONG Xinru, YANG Deying, GUAN Tangming, CHEN Ju, JIANG Dongbo.
Research Progress in Adverse Reactions Caused by Obinutuzumab in the Treatment of Follicular Lymphoma
[J]. Chinese Journal of Pharmacovigilance, 2025, 22(7): 831-835.
|
[5] |
YE Ling, LIU Xiaoying, DANG Xuefei, LI Xuelian, LI Gang.
Research Progress in Drugs for Brain Metastases from Advanced Breast Cancer
[J]. Chinese Journal of Pharmacovigilance, 2025, 22(6): 714-720.
|
[6] |
XIE Ziyue, WANG Chengxiang, HU Yanpeng, LI Lei, CUI Herong.
Clinical Medications and Safety Analysis of Traditional Chinese Medicine for Post-Infection Cough
[J]. Chinese Journal of Pharmacovigilance, 2025, 22(5): 507-512.
|
[7] |
LI Can, LIU Lehuan, CHEN Xia, QU Jianbo.
Pharmacy of Chinese Medicine Compound Preparations Based on Human Experiences
[J]. Chinese Journal of Pharmacovigilance, 2025, 22(5): 564-569.
|
[8] |
WANG Han, WANG Cunxuan, LYU Xuehaiyue, ZHANG Lining, SUO Yusi, GU Zhi'en, WANG Ping, JIN Xuejing.
Chinese Patent Medicines for Preventing Myelosuppression in Adjuvant Treatment of Malignant Tumors: a Systematic Review and Network Meta-Analysis
[J]. Chinese Journal of Pharmacovigilance, 2025, 22(2): 169-176.
|
[9] |
NIE Xiaolu, SUN Feng, YAN Aixia, PENG Xiaoxia, ZHAN Siyan.
Methodology for Constructing Benchmark Database of Adverse Drug Reactions Based on Multi-Source Information
[J]. Chinese Journal of Pharmacovigilance, 2025, 22(1): 10-15.
|
[10] |
LI Wenlong, JIA Juanjuan, HUANG Haiwei, YAO Jing, ZHANG Chunqing, WANG Yan, ZHANG Hui.
Developments and Prospects of Radiopharmaceuticals in China
[J]. Chinese Journal of Pharmacovigilance, 2025, 22(1): 37-42.
|
[11] |
HOU Tiantian, WANG Xudong, YANG Ping, ZHOU Pengbo, QIN Chao, HUANG Ying, WANG Ailing, GENG Xingchao, ZHOU Xiaobing, LIU Defang.
Biodistribution of Therapeutic DNA Vaccines in Mice
[J]. Chinese Journal of Pharmacovigilance, 2025, 22(1): 58-66.
|
[12] |
LU Zhenkai, YANG Dingquan, XIE Zhennian, WANG Lianxin, LI Yuanyuan, WANG Zhifei, CUI Xin, XIE Yanming.
Interpretation and insights from the “Guidelines for Pharmacovigilance of Topical Traditional Chinese Medicines in Clinical Applications”
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(9): 1029-1033.
|
[13] |
WANG Yijin, TANG Jing, YANG Chao, XU Kai, ZHANG Mengdie, GAO Jian, WU Xiaoli, ZHANG Yue, NIU Xiaobing, JIANG Hesong, MAO Fei, ZHOU Shan, JIANG Xi, GUO Zhongying, SUN Su'an, XU Ming, XU Zongyuan, WANG Hengbing, LI Xin, FU Guangbo.
Clinical research of submucosal low-dose gemcitabine injection combined with transurethral resection of bladder tumor in the treatment of medium-high risk non-muscle invasive bladder cancer
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(9): 1044-1050.
|
[14] |
LIU Yan, AN Jing, JIAO Yongzhuo, LIANG Xuefeng, ZHANG Xiaoshu.
Simple febrile seizures within 30 days of vaccination with the measles, mumps and rubella combined attenuated live vaccine in U-12 children in the real world
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(7): 805-810.
|
[15] |
ZHAO Xuan, ZHENG Tingting, LI Xuemei, MAO Lu, GUO Jing, ZHANG Wei.
Adverse reaction reports of vancomycin in a hospital
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(7): 811-815.
|